目的探讨术前新辅助内分泌治疗在老年乳腺癌治疗中的意义。
Objective To study the curative effect of preoperative endocrine therapy on breast cancer in elderly women.
术后辅助内分泌治疗联合放疗的综合治疗可显著延长无生化复发生存时间。
Multi-modal treatment like adjuvant androgen deprivation therapy plus radiotherapy can greatly improve the biochemical recurrence-free survival.
结论年龄并不是乳腺癌根治术的禁忌，且老年患者从辅助内分泌治疗中获益较多。
Conclusion Age is not the taboo of radical mastectomy, and elderly patients benefit from adjuvant endocrine therapy for more.
这项研究结果也显示，相比较新辅助化疗，罕见对新辅助内分泌治疗有完全的缓解。
The results also indicate that a complete response to neoadjuvant endocrine therapy is rare compared to neoadjuvant chemotherapy.
结论术前新辅助内分泌治疗在高龄乳腺癌患者中能达到原发病灶和区域淋巴结降期的目的。
Conclusion Preoperative endocrine therapy for breast cancer of elderly women could effectively delay or remit the advancement of the tumor.
术前辅以新辅助化疗，术后辅以正规内分泌治疗是提高局部晚期乳腺癌生存率的必要手段。
The neoadjuvant chemotherapy and regular endocrine therapy are the necessary measures to improve the survival rates of locally advanced breast cancer.
内分泌治疗的远期影响仍然是一个问题，这是因为乳腺癌存活者的人数以及辅助治疗的持续时间都在增长。
The long-term impact of these endocrine manipulations is an issue, because the duration of adjuvant treatment is still increasing, as is the number of breast cancer survivors.
选择性COX - 2抑制剂可联合化疗、内分泌治疗及生物治疗等，作为肿瘤治疗的辅助药物应用于临床，为乳腺癌的治疗提供一种新的途径。
Selective COX-2 inhibitors can combine with chemotherapy, endocrine therapy and biotherapy. It is gradually used for adjunctive therapy and provides a new pathway for the therapy of breast cancer.
术后常规行辅助放疗、化疗和内分泌治疗。
Routine adjuvant irradiation, chemotherapy and hormone therapy were given postoperatively.
在美国，研究人员称少数裔及40岁以下、80岁以上乳腺癌女性患者不经常接受内分泌辅助治疗，存在生存风险。
In the U. S, minorities and women under 40 and over 80 frequently don't receive adjuvant endocrine therapy (AET) for breast cancer, putting their lives at risk, researchers say.
术后常规行辅助放疗、化疗和内分泌治疗。
Adjuvant irradiation, chemotherapy and hormone therapy were given postoperatively.
结论手术切除是治疗分化型甲状腺癌的主要手段，采取适当的手术方式，辅助术后内分泌治疗，可提高生存率。
Conclusion Surgical procedure plays the key role in the treatment of differentiated thyroid cancer. Combined with endocrine therapy, the proper modus operandi can elevate the survival rate.
结果：36例患者中29例(80%)经新辅助治疗后病情缓解，可以手术。其中27例由化疗获得，2例由内分泌治疗获得。
Results: After neoadjuvant therapy, 29 (80%) patients got partial response and some of the primary inoperable lesions became respectable, 27cases by chemotherapy, 2cases by endocrine therapy.
结果：36例患者中29例(80%)经新辅助治疗后病情缓解，可以手术。其中27例由化疗获得，2例由内分泌治疗获得。
Results: After neoadjuvant therapy, 29 (80%) patients got partial response and some of the primary inoperable lesions became respectable, 27cases by chemotherapy, 2cases by endocrine therapy.
应用推荐